A Phase 4 interventional study of amlodipine/benazepril in Albuminuria, sponsored by Novartis. Completed. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-03-09.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.
144 studies on the registry are indexed under Albuminuria; 25 are open to participants now.
This study's enrollment of 332 is above the median of 69 across 117 interventional studies indexed under Albuminuria.
Browse Albuminuria studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BenazeprilStudies of BenazeprilBenazepril pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Change from baseline in the urine albumin/creatinine ratio after 52 weeks
Percentage of patients who have progressed to diabetic kidney disease (urine albumin/creatinine ratio ≥ 300 µg/mg creatinine) after 52 weeks
Change from baseline in the ratio of urine albumin/creatinine ratio an estimate of kidney function after 52 weeks
Change from baseline in insulin resistance after 52 weeks
Change from baseline in urine albumin secretion after 52 weeks
Change from baseline in a marker of heart failure after 52 weeks
No study locations are listed for this record.
The record gives a start of Apr 2003, a primary completion of Oct 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Benazepril